TNFRSF9 is an activation marker for tumor-infiltrating Tregs, and inhibition of TNFRSF9 boosts anti-cancer treatments via reducing the immune suppressive function of Tregs29. This evidence concerns the gene TNFRSF9 and neoplasm.